Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003025149A3 Cell populations which co-express cd49c and cd90
12/18/2003WO2003016540A3 Humanised baculovirus
12/18/2003WO2003015773A3 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
12/18/2003WO2003013536A3 Methods for treatment of cancer using irinotecan based on ugt1a1
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002101049A3 Interleukin-18 mutants, their production and use
12/18/2003WO2002100899A3 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
12/18/2003WO2002092781A3 Peptide compounds for counteracting reactive oxygen species and free radicals
12/18/2003WO2002085305A3 Compositions and methods for inducing cancer cell death
12/18/2003WO2002083030A3 Bifunctional energy-reversible acyl-compositions
12/18/2003WO2002081668A3 Desaturase genes and uses thereof
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002078599A3 CD8α + LYMPHOID DENDRITIC CELL DIFFERENTIATED FROM HUMAN HEMATOPOIETIC STEM CELL AND A METHOD FOR DIFFERENTIATION
12/18/2003WO2002067941A8 Combination comprising a signal transduction inhibitor and an epothilone derivative
12/18/2003WO2002062398A3 Radioactively labelled conjugates of phosphonates
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
12/18/2003WO2002057492A9 Methods and compositions for detecting polynucleotide duplex damage
12/18/2003WO2002042443A3 Use of modulators of eukaryotic signal transduction pathways for the treatment of helicobacter infections
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour
12/18/2003WO2002014536A9 Odulating multiple lineage kinase proteins
12/18/2003WO2002007678A3 Mu-conopeptides
12/18/2003US20030233045 Solid hydrogel coupling for ultrasound imaging and therapy
12/18/2003US20030233000 Bryostatin composition and bryostatin acquisition methodologies
12/18/2003US20030232986 Inhibitors of caspases
12/18/2003US20030232889 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain
12/18/2003US20030232887 Preparation and use of a stable formulation of allosteric effector compounds
12/18/2003US20030232880 For therapy of pain, fever or inflammation to inhibit prostanoid-induced smooth muscle contraction; for prophylaxis and therapy of colorectal cancer or neurodegenerative diseases
12/18/2003US20030232874 Methods and compositions for the treatment of chronic lymphocytic leukemia
12/18/2003US20030232869 N3 alkylated benzimidazole derivatives as MEK inhibitors
12/18/2003US20030232863 Cathepsin cysteine protease inhibitors
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232854 Such as 3-methyl-5-(2-chloro-6-fluorophenyl)-4-isoxazole-carboxylic acid ethyl ester for inhibiting multidrug resistance protein (MRP1)
12/18/2003US20030232849 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/18/2003US20030232848 Pyrazole compositions
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232845 Enzyme hydrolase inhibitors such as 1-ethyl-3,7-dihydro-8-((1 R,2R)-(hydroxycyclopentyl)amino)-3-(2-hydroxyethyl)-7-((3-bromo-4 -methoxyphenyl)methyl)-1H-Purine-2,6-dione, used for physiological effects
12/18/2003US20030232844 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders
12/18/2003US20030232841 Amides such as 5-(2-(4-methylpiperazin-1-yl)-phenyl)-furan-2-carboxylic acid 4-chlorobenzylamide, used as antidepressants and for prophylaxis of headaches
12/18/2003US20030232837 17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
12/18/2003US20030232823 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232797 Useful as immunomodulating and antiinflammatory compounds and in treatment of cardiovascular disease and cancer
12/18/2003US20030232795 Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity
12/18/2003US20030232790 Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase
12/18/2003US20030232789 Salicylamides as serine protease and factor xa inhibitors
12/18/2003US20030232767 Activating cancerous cells response to therapeutic agents, by administering cisplatin or oxaliplatin, applying ionizing radiation and hydrogen peroxide
12/18/2003US20030232765 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
12/18/2003US20030232763 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
12/18/2003US20030232755 Antitumor agents, anticarcinogenic agents, replacing another amino acid at 86, 87, and 88 of the amino acid sequence
12/18/2003US20030232753 Combined tissue factor methods for coagulation and tumor treatment
12/18/2003US20030232752 Proliferated cell lines and uses thereof
12/18/2003US20030232433 The use of stem cells and CD6 depleted stem cells for the induction of tolerance to allogenic transplants and/or for the treatment of leucemia
12/18/2003US20030232362 A protein which excretes cancer chemotherapeutic drugs from a cell and which confers drug- resistance on the cell, a DNA encoding the protein, a method for detecting a cell type resistant to cancer chemotherapeutic drugs
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003US20030232334 Novel compositions and methods for cancer
12/18/2003US20030232326 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
12/18/2003US20030232074 For stimulating immune activation; for screening immunostimulatory compounds
12/18/2003US20030232063 Aminosulfonic acid compounds for promoting desquamation of the skin
12/18/2003US20030232053 Administering to treat rheumatoid arthritis, cancer, restenosis
12/18/2003US20030232049 Multispecific reagent for selectively stimulating cell surface receptors
12/18/2003US20030232012 For use as in vivo contrast media in nuclear spin tomography (MRT), as blood-pool agents and as lymphographic agents
12/18/2003DE10215316C1 Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer Quinoline and isoquinoline derivatives, to a pharmaceutical agent and their use as anti-inflammatory agents
12/18/2003CA2590618A1 Method of treating cancer using kinase inhibitors
12/18/2003CA2493890A1 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003CA2490037A1 Galactosyl isomalt, a method for producing it and its use
12/18/2003CA2489282A1 Medical device for intra-lumenal delivery of pharmaceutical agents
12/18/2003CA2489153A1 Modified byrodin 1 with reduced immunogenicity
12/18/2003CA2488974A1 Medicament for treatment of cancer
12/18/2003CA2488801A1 Ether substituted imidazopyridines
12/18/2003CA2488798A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488682A1 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
12/18/2003CA2488618A1 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
12/18/2003CA2488609A1 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003CA2488602A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488403A1 Pharmaceutical formulation
12/18/2003CA2488402A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003CA2488385A1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003CA2488360A1 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
12/18/2003CA2488358A1 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
12/18/2003CA2488356A1 Novel therapeutic use of polypodium extracts
12/18/2003CA2488347A1 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003CA2488246A1 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
12/18/2003CA2488108A1 Liquid formulation of decitabine and use of the same
12/18/2003CA2487983A1 Method of treating cancer using kinase inhibitors
12/18/2003CA2487924A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003CA2487907A1 Immunogenic compositions comprising a xenogenic prostate protein p501s
12/18/2003CA2487889A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
12/18/2003CA2487866A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
12/18/2003CA2487838A1 Methods and compounds for inhibiting the cytokine or biological activity of mif
12/18/2003CA2487418A1 Metalloproteinase inhibitors
12/18/2003CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003CA2487147A1 Combinations comprising epothilones and pharmaceutical uses thereof
12/18/2003CA2487077A1 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
12/18/2003CA2486491A1 4-(aryl or heteroaryl)-2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003CA2486362A1 Novel recombinant anticoagulant proteins
12/17/2003EP1371729A2 Use of ttf3 ligands for the diagnosis and therapy of cancer
12/17/2003EP1371664A1 Wti modified peptide
12/17/2003EP1371650A1 Activator for peroxisome proliferator-activated receptor
1 ... 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 ... 2211